Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Trends Indicate Global Improvement in Cancer Survival

February 2, 2018
By Mark L. Fuerst
Article

The largest and most up-to-date study of international cancer registries shows that survival trends are generally increasing, even for some lethal cancers.

The largest and most up-to-date study of international cancer registries shows that survival trends are generally increasing, even for some of the more lethal cancers, such as liver and lung.

The CONCORD-3 study analyzed individual patient records from 322 cancer registries in 71 countries and territories to compare 5-year survival from diagnosis for more than 37.5 million adults and children with one of 18 common cancers. These cancers represent three-quarters of all cancers diagnosed worldwide every year between 2000 and 2014. The researchers published their results in the Lancet.

“Continuous monitoring of global trends in cancer survival is crucial to assess the overall effectiveness of health systems worldwide, and to help policy-makers plan better strategies for cancer control. But, inadequate or unreliable data prevent governments from understanding the true nature and magnitude of the public health problems created by the growing cancer burden. This leaves governments poorly equipped to develop national cancer plans that will translate into real improvements in survival for patients,” said lead author Claudia Allemani, PhD, of the Cancer Survival Group at the London School of Hygiene & Tropical Medicine.

For most cancers, 5-year net survival remains the highest in the world in the United States, Canada, Australia, New Zealand, Finland, Iceland, Norway, and Sweden. In some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung, which are some of the more lethal cancers.

Survival for most cancers remains highest in a handful of countries. For women diagnosed with breast cancer in the United States and Australia, the 5-year survival rate is 90% compared with 66% for women diagnosed in India. Within Europe, the 5-year breast cancer survival rate increased to 85% or more in 16 countries, as compared with a low of 71% in Russia.

For gastrointestinal cancers, the highest levels of 5-year survival are seen in Southeast Asia. This could be due to long-standing population-based endoscopic screening programs. By contrast, in the same region, survival is generally lower than elsewhere for melanoma of the skin and for both lymphoid and myeloid malignancies.

Not all major cancers have seen large improvements. Even in 2014, pancreatic cancer remained highly lethal in all countries, with 5-year survival typically less than 15%.

A wide gulf in survival exists for childhood cancers. Five-year survival rates for acute lymphoblastic leukemia ranged from higher than 90% in Canada, the United States, and nine European countries to below 60% in China, Mexico, and Ecuador. For brain tumors, 5-year survival rates in children are higher than for adults, but range widely globally, from 28.9% in Brazil to nearly 80% in Sweden and Denmark.

The researchers noted that cancer registries should be given adequate resources to register all patients and to link the registry data to up-to-date death records. “Governments must recognize cancer registries as efficient public health instruments that produce a continuous stream of valuable information on both the impact of cancer prevention strategies and the effectiveness of health systems, and at very low cost,” they concluded.

Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
Advertisement

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Chris Ryan
October 17th 2025
Article

Osimertinib plus chemotherapy significantly improved overall survival in EGFR-mutated NSCLC, outperforming monotherapy across various prognostic factors.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.

Local Consolidative Therapy Plus Osimertinib Yields PFS Benefit in Metastatic EGFR-Mutant NSCLC

Kristi Rosa
October 17th 2025
Article

Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Kyle Doherty
October 17th 2025
Article

Adjuvant ribociclib plus aromatase inhibitors significantly improved invasive disease-free survival in early breast cancer, as shown in the NATALEE trial.


Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

Abemaciclib Regimen Improves Survival in HR+/HER2– Early Breast Cancer

Ashling Wahner
October 17th 2025
Article

Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

Related Content
Advertisement

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Chris Ryan
October 17th 2025
Article

Osimertinib plus chemotherapy significantly improved overall survival in EGFR-mutated NSCLC, outperforming monotherapy across various prognostic factors.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.

Local Consolidative Therapy Plus Osimertinib Yields PFS Benefit in Metastatic EGFR-Mutant NSCLC

Kristi Rosa
October 17th 2025
Article

Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Kyle Doherty
October 17th 2025
Article

Adjuvant ribociclib plus aromatase inhibitors significantly improved invasive disease-free survival in early breast cancer, as shown in the NATALEE trial.


Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

Abemaciclib Regimen Improves Survival in HR+/HER2– Early Breast Cancer

Ashling Wahner
October 17th 2025
Article

Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.